Issue Contents:  Sep 9, 2010

• ZymoGenetics Skyrockets 84% on $885M BMS Offer
• For $339M Onyx Carves Out Carfilzomib Japanese Rights
• Two Studies Identify Same Culprit In Ovarian Cancer
• Jennerex, Transgene in $116M Deal; Liver Cancer Trial First
• Zyngenia Adds $15M to Push Multitarget Antibodies to IND
• Vertex Reports Positive HCV Data, 65% Overall Viral Cure
• Stock Movers
• Clinic Roundup
• Other News To Note

      The above issue is also available as one PDF File